ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study

ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study

Abstract Background ModraDoc006 is an oral formulation of docetaxel, which is co‐administered with the cytochrome P450 3A4 and P‐glycoprotein inhibitor ritonavir (r): ModraDoc006/r. Weekly treatment with ModraDoc006/r had been evaluated in phase I trials in patients with different types of advanced...

Full description

Bibliographic Details
Main Authors: Marit A. C. Vermunt, Debbie G. J. Robbrecht, Lot A. Devriese, Julie M. Janssen, Bas Thijssen, Marianne Keessen, Maarten vanEijk, Rob Kessels, Ferry A. L. M. Eskens, Jos H. Beijnen, Niven Mehra, Andries M. Bergman
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Cancer Reports
Subjects:
chemotherapy
clinical trials
drug discovery and delivery
prostate cancer
Online Access:https://doi.org/10.1002/cnr2.1367

Internet

https://doi.org/10.1002/cnr2.1367

Similar Items